Mesenchymal stem cell therapy for COVID-19 infection
- 20 December 2023
- journal article
- review article
- Published by Springer Nature in Inflammopharmacology
- Vol. 32 (1) , 319-334
Abstract
COVID-19 emerged in December 2019 in Wuhan, China, spread worldwide rapidly, and caused millions of deaths in a short time. Many preclinical and clinical studies were performed to discover the most efficient therapy to reduce the mortality of COVID-19 patients. Among various approaches for preventing and treating COVID-19, mesenchymal stem cell (MSC) therapy can be regarded as a novel and efficient treatment for managing COVID-19 patients. In this review, we explain the pathogenesis of COVID-19 infection in humans and discuss the role of MSCs in suppressing the inflammation and cytokine storm produced by COVID-19. Then, we reviewed the clinical trial and systematic review studies that investigated the safety and efficacy of MSC therapy in the treatment of COVID-19 infection.Keywords
This publication has 63 references indexed in Scilit:
- Human umbilical cord mesenchymal stem cells: an overview of their potential in cell-based therapyExpert Opinion on Biological Therapy, 2015
- Cell Adhesion and Long-Term Survival of Transplanted Mesenchymal Stem Cells: A Prerequisite for Cell TherapyOxidative Medicine and Cellular Longevity, 2015
- Secretion of immunoregulatory cytokines by mesenchymal stem cellsWorld Journal of Stem Cells, 2014
- Adipose-derived mesenchymal stromal/stem cells: An update on their phenotype in vivo and in vitroWorld Journal of Stem Cells, 2014
- Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cellsStem Cell Research & Therapy, 2013
- Adipose-Derived Mesenchymal Stromal/Stem Cells: Tissue Localization, Characterization, and HeterogeneityStem Cells International, 2012
- Mesenchymal stem cell effects on T-cell effector pathwaysStem Cell Research & Therapy, 2011
- Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in idiopathic pulmonary fibrosis (IPF)Respiratory Medicine, 2010
- Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2010
- Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitroRheumatology, 2006